Protocol
Moxidectin in Onchocerciasis: Ongoing Clinical Trial Protocols 3
MDGH-MOX-1006: A pharmacokinetic and safety study of moxidectin to identify an optimal dose for treatment of children 4 to 11 years (Target: at least 27 participants)
MDGH-MOX-1006: A pharmacokinetic and safety study of moxidectin to identify an optimal dose for treatment of children 4 to 11 years (Target: at least 27 participants)
Stay up to date
Follow our work by signing up for our newsletter.
Search the site
MDGH respectfully acknowledges the Traditional Owners of the land on which our office is located, the Wurundjeri people of the Kulin Nation, and pay our respect to their Elders past, present and emerging.